Clinical and pharmacological study of intrahepatic artery infusion of Thiotepa

Lynn G Feun, G. Blyden, Jose Yrizarry, M. Dorvil, S. Waldman, Pasquale W Benedetto, E. Donnelly, J. Curtas, M. George, Niramol Savaraj

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Twenty patients with primary or metastatic liver cancer were treated on a clinical and pharmacological study with intrahepatic artery infusion of Thiotepa. Toxicity was tolerable and included nausea and fatigue. Uncommon side effects were myelosuppression, abdominal pain and anemia. One patient with gallbladder cancer had a partial response for 11 (+) months. Recommended dose of Thiotepa for future Phase II clinical trials is 1.0 mg/kg. Pharmacokinetics of intrahepatic Thiotepa revealed an extraction ratio similar to that reported for cisplatin. The data suggest increased hepatic clearance for Thiotepa either by binding or metabolism.

Original languageEnglish
Pages (from-to)43-48
Number of pages6
JournalCancer Biotherapy
Volume8
Issue number1
StatePublished - Jan 1 1993

Fingerprint

Thiotepa
Arteries
Pharmacology
Gallbladder Neoplasms
Phase II Clinical Trials
Liver Neoplasms
Nausea
Abdominal Pain
Cisplatin
Fatigue
Anemia
Pharmacokinetics
Clinical Studies
Liver

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Clinical and pharmacological study of intrahepatic artery infusion of Thiotepa. / Feun, Lynn G; Blyden, G.; Yrizarry, Jose; Dorvil, M.; Waldman, S.; Benedetto, Pasquale W; Donnelly, E.; Curtas, J.; George, M.; Savaraj, Niramol.

In: Cancer Biotherapy, Vol. 8, No. 1, 01.01.1993, p. 43-48.

Research output: Contribution to journalArticle

Feun, LG, Blyden, G, Yrizarry, J, Dorvil, M, Waldman, S, Benedetto, PW, Donnelly, E, Curtas, J, George, M & Savaraj, N 1993, 'Clinical and pharmacological study of intrahepatic artery infusion of Thiotepa', Cancer Biotherapy, vol. 8, no. 1, pp. 43-48.
Feun, Lynn G ; Blyden, G. ; Yrizarry, Jose ; Dorvil, M. ; Waldman, S. ; Benedetto, Pasquale W ; Donnelly, E. ; Curtas, J. ; George, M. ; Savaraj, Niramol. / Clinical and pharmacological study of intrahepatic artery infusion of Thiotepa. In: Cancer Biotherapy. 1993 ; Vol. 8, No. 1. pp. 43-48.
@article{5e6448f8dc20473daa39557e1d4a21a1,
title = "Clinical and pharmacological study of intrahepatic artery infusion of Thiotepa",
abstract = "Twenty patients with primary or metastatic liver cancer were treated on a clinical and pharmacological study with intrahepatic artery infusion of Thiotepa. Toxicity was tolerable and included nausea and fatigue. Uncommon side effects were myelosuppression, abdominal pain and anemia. One patient with gallbladder cancer had a partial response for 11 (+) months. Recommended dose of Thiotepa for future Phase II clinical trials is 1.0 mg/kg. Pharmacokinetics of intrahepatic Thiotepa revealed an extraction ratio similar to that reported for cisplatin. The data suggest increased hepatic clearance for Thiotepa either by binding or metabolism.",
author = "Feun, {Lynn G} and G. Blyden and Jose Yrizarry and M. Dorvil and S. Waldman and Benedetto, {Pasquale W} and E. Donnelly and J. Curtas and M. George and Niramol Savaraj",
year = "1993",
month = "1",
day = "1",
language = "English",
volume = "8",
pages = "43--48",
journal = "Cancer Biotherapy",
issn = "1062-8401",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Clinical and pharmacological study of intrahepatic artery infusion of Thiotepa

AU - Feun, Lynn G

AU - Blyden, G.

AU - Yrizarry, Jose

AU - Dorvil, M.

AU - Waldman, S.

AU - Benedetto, Pasquale W

AU - Donnelly, E.

AU - Curtas, J.

AU - George, M.

AU - Savaraj, Niramol

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Twenty patients with primary or metastatic liver cancer were treated on a clinical and pharmacological study with intrahepatic artery infusion of Thiotepa. Toxicity was tolerable and included nausea and fatigue. Uncommon side effects were myelosuppression, abdominal pain and anemia. One patient with gallbladder cancer had a partial response for 11 (+) months. Recommended dose of Thiotepa for future Phase II clinical trials is 1.0 mg/kg. Pharmacokinetics of intrahepatic Thiotepa revealed an extraction ratio similar to that reported for cisplatin. The data suggest increased hepatic clearance for Thiotepa either by binding or metabolism.

AB - Twenty patients with primary or metastatic liver cancer were treated on a clinical and pharmacological study with intrahepatic artery infusion of Thiotepa. Toxicity was tolerable and included nausea and fatigue. Uncommon side effects were myelosuppression, abdominal pain and anemia. One patient with gallbladder cancer had a partial response for 11 (+) months. Recommended dose of Thiotepa for future Phase II clinical trials is 1.0 mg/kg. Pharmacokinetics of intrahepatic Thiotepa revealed an extraction ratio similar to that reported for cisplatin. The data suggest increased hepatic clearance for Thiotepa either by binding or metabolism.

UR - http://www.scopus.com/inward/record.url?scp=0027362171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027362171&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 43

EP - 48

JO - Cancer Biotherapy

JF - Cancer Biotherapy

SN - 1062-8401

IS - 1

ER -